Display options
Cite
Baldi BG, Radzikowska E, Cottin V, et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021;doi: 10.1016/j.chest.2021.12.640.
Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Ribeiro Carvalho, C. R., Harari, S., Koslow, M., Grutters, J. C., Inoue, Y., Gupta, N., & Johnson, S. R. (2021). COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest, . https://doi.org/10.1016/j.chest.2021.12.640
Baldi, Bruno Guedes, et al. "COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.12.640
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20. PMID: 34942174.
Copy Download .nbib Format: NLM
Share it on

Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20.

COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition.

Chest

Bruno Guedes Baldi, Elzbieta Radzikowska, Vincent Cottin, Daniel F Dilling, Ali Ataya, Carlos Roberto Ribeiro Carvalho, Sergio Harari, Matthew Koslow, Jan C Grutters, Yoshikazu Inoue, Nishant Gupta, Simon R Johnson

Affiliations

  1. Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Electronic address: [email protected].
  2. National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
  3. National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INRAE, Lyon, France.
  4. Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
  5. Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA.
  6. Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  7. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Department of Medicine, Ospedale San Giuseppe MultiMedica IRCCS, Milan, Italy.
  8. ILD Program, Department of Medicine, National Jewish Health, Denver, CO, USA.
  9. ILD Center of Excellence, St. Antonius Hospital Nieuwegein. University Medical Center Utrecht, The Netherlands.
  10. Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
  11. Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati USA.
  12. Translational Medical Sciences, NIHR Biomedical Research Centre and Biodiscovery Institute, University of Nottingham, Nottingham, UK; National Centre for Lymphangioleiomyomatosis. Nottingham University Hospitals NHS Trust, Nottingham, UK.

PMID: 34942174 DOI: 10.1016/j.chest.2021.12.640

[No abstract available.]

Keywords: Hospitalization; LAM; TSC; patient outcome assessment; sirolimus

Publication Types